$Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma$
Código QR

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma

Abstract Belantamab mafodotin (belamaf) is an antibody–drug conjugate (ADC) targeting B‐cell maturation antigen (BCMA). Nonlinear mixed‐effects models were developed to characterize the population pharmacokinetics (PopPK) of ADC, total monoclonal antibody (mAb), and cysteine‐maleimidocaproyl‐MMAF (c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chetan Rathi, Jon Collins, Herbert Struemper, Joanna Opalinska, Roxanne C. Jewell, Geraldine Ferron‐Brady
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/54aded09da294383a33b92e887443362
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:54aded09da294383a33b92e887443362
record_format	dspace
spelling	oai:doaj.org-article:54aded09da294383a33b92e8874433622021-11-19T15:35:29ZPopulation pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma2163-830610.1002/psp4.12660https://doaj.org/article/54aded09da294383a33b92e8874433622021-08-01T00:00:00Zhttps://doi.org/10.1002/psp4.12660https://doaj.org/toc/2163-8306Abstract Belantamab mafodotin (belamaf) is an antibody–drug conjugate (ADC) targeting B‐cell maturation antigen (BCMA). Nonlinear mixed‐effects models were developed to characterize the population pharmacokinetics (PopPK) of ADC, total monoclonal antibody (mAb), and cysteine‐maleimidocaproyl‐MMAF (cys‐mcMMAF) after 0.03–4.6 mg/kg dosing every 3 weeks in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM; DREAMM‐1, n = 73; DREAMM‐2, n = 218). Sequential modeling methodology was used. Individual post hoc parameter estimates from the final ADC model were used to develop total mAb and cys‐mcMMAF models. Formal covariate selection used a modified stepwise forward inclusion method with backward elimination. A linear, two‐compartment PopPK model with a time‐varying clearance (CL) described ADC PK. Initial ADC typical value for CL for a DREAMM‐2 patient was 0.936 L/day with a half‐life of 11.5 days, over time CL was reduced by 28% resulting in a half‐life of 14.3 days. Time to 50% maximal CL change was ~ 50 days. Baseline soluble BCMA (sBCMA), immunoglobulin (IgG), albumin, and bodyweight impacted ADC CL. Cys‐mcMMAF concentrations were described with a linear two‐compartment model linked to ADC; input rate was governed by deconjugation/intracellular proteolytic degradation of ADC represented by an exponentially decreasing MMAF:mAb (drug antibody ratio [DAR]) after each dose. Time to 50% DAR reduction was 10.3 days. Baseline sBCMA and IgG impacted cys‐mcMMAF central volume of distribution. In conclusion, ADC, total mAb, and cys‐mcMMAF concentration–time profiles in RRMM were well‐described by PopPK models, and exposure was most strongly impacted by disease‐related characteristics.Chetan RathiJon CollinsHerbert StruemperJoanna OpalinskaRoxanne C. JewellGeraldine Ferron‐BradyWileyarticleTherapeutics. PharmacologyRM1-950ENCPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 851-863 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Chetan Rathi Jon Collins Herbert Struemper Joanna Opalinska Roxanne C. Jewell Geraldine Ferron‐Brady Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
description	Abstract Belantamab mafodotin (belamaf) is an antibody–drug conjugate (ADC) targeting B‐cell maturation antigen (BCMA). Nonlinear mixed‐effects models were developed to characterize the population pharmacokinetics (PopPK) of ADC, total monoclonal antibody (mAb), and cysteine‐maleimidocaproyl‐MMAF (cys‐mcMMAF) after 0.03–4.6 mg/kg dosing every 3 weeks in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM; DREAMM‐1, n = 73; DREAMM‐2, n = 218). Sequential modeling methodology was used. Individual post hoc parameter estimates from the final ADC model were used to develop total mAb and cys‐mcMMAF models. Formal covariate selection used a modified stepwise forward inclusion method with backward elimination. A linear, two‐compartment PopPK model with a time‐varying clearance (CL) described ADC PK. Initial ADC typical value for CL for a DREAMM‐2 patient was 0.936 L/day with a half‐life of 11.5 days, over time CL was reduced by 28% resulting in a half‐life of 14.3 days. Time to 50% maximal CL change was ~ 50 days. Baseline soluble BCMA (sBCMA), immunoglobulin (IgG), albumin, and bodyweight impacted ADC CL. Cys‐mcMMAF concentrations were described with a linear two‐compartment model linked to ADC; input rate was governed by deconjugation/intracellular proteolytic degradation of ADC represented by an exponentially decreasing MMAF:mAb (drug antibody ratio [DAR]) after each dose. Time to 50% DAR reduction was 10.3 days. Baseline sBCMA and IgG impacted cys‐mcMMAF central volume of distribution. In conclusion, ADC, total mAb, and cys‐mcMMAF concentration–time profiles in RRMM were well‐described by PopPK models, and exposure was most strongly impacted by disease‐related characteristics.
format	article
author	Chetan Rathi Jon Collins Herbert Struemper Joanna Opalinska Roxanne C. Jewell Geraldine Ferron‐Brady
author_facet	Chetan Rathi Jon Collins Herbert Struemper Joanna Opalinska Roxanne C. Jewell Geraldine Ferron‐Brady
author_sort	Chetan Rathi
title	Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
title_short	Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
title_full	Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
title_fullStr	Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
title_full_unstemmed	Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
title_sort	population pharmacokinetics of belantamab mafodotin, a bcma‐targeting agent in patients with relapsed/refractory multiple myeloma
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/54aded09da294383a33b92e887443362
work_keys_str_mv	AT chetanrathi populationpharmacokineticsofbelantamabmafodotinabcmatargetingagentinpatientswithrelapsedrefractorymultiplemyeloma AT joncollins populationpharmacokineticsofbelantamabmafodotinabcmatargetingagentinpatientswithrelapsedrefractorymultiplemyeloma AT herbertstruemper populationpharmacokineticsofbelantamabmafodotinabcmatargetingagentinpatientswithrelapsedrefractorymultiplemyeloma AT joannaopalinska populationpharmacokineticsofbelantamabmafodotinabcmatargetingagentinpatientswithrelapsedrefractorymultiplemyeloma AT roxannecjewell populationpharmacokineticsofbelantamabmafodotinabcmatargetingagentinpatientswithrelapsedrefractorymultiplemyeloma AT geraldineferronbrady populationpharmacokineticsofbelantamabmafodotinabcmatargetingagentinpatientswithrelapsedrefractorymultiplemyeloma
_version_	1718420012705775616

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma

Ejemplares similares